Corrigendum: Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial (Annals of Oncology (2016) 27 (2196-2203) DOI: 10.1093/annonc/mdw423)